Journal of Oncology / 2019 / Article / Tab 1 / Research Article
Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials Table 1 Study characteristics of the included studies.
No Reference Country N patientsGender (M/F) Age KPS Tumor site Stage Follow-up (median or mean) Arm Dose/fraction (Gy) Total dose (Gy) 1 Pan et al. [15 ] China 200 150/50 49 (18–70) ≥70 Nasopharynx I–IV 6.9 years HART 1.2–1.5 78 CFRT 2 70 2 Wang et al. [16 ] China 98 63/35 65 (55–74) ≥70 Esophageal — 45 (36–58) months HART 1.5 64 (61–67) CFRT 2 64 (60–68) 3 Dobrowsky and Naude [9 ] Ireland 159 139/22 34–77 90–100 Oral cavity Oropharynx Hypopharynx Larynx T1–T4 N0–N3 48 months HART 1.65–2.5 55.3 CFRT 2 70 4 Teo et al. [17 ] China 159 122/37 — — Nasopharynx II–IV 59.2 months HART 1.5 22.4 CFRT 2.5 20 5 Shi et al. [18 ] China 85 50/35 55.6 >70 Esophagus — 5 years HART 1.5–1.8 68.4 CFRT 1.8 68.4 6 Fallai et al. [11 ] Italy 128 112/16 — ≥70 Oropharynx III-IV 8.35 (4.8–10.2) years HART 1.6 64–67.2 CFRT — 66–70 7 Saunders et al. [19 ] United Kingdom 918 — — — — T2–T4 N0-N1 M0 ≤6 years HART 1.5 54 CFRT 2 66 8 El-Weshi et al. [20 ] Egypt 50 40/10 39.9 (18–63) — Nasopharynx III-IV 55 (4–120) months HART 1.6 72 CFRT 2 72 9 Miszczyk et al. [21 ] Poland 101 78/23 57 (42–73) — Excluding nasopharynx T2N3 T3N03 T4N0-N3 — HART 1.6 64 CFRT 2 50 10 Awwad et al. [12 ] Egypt 70 56/14 50 (25–65) — Oral cavity Hypopharynx Larynx T2–T4 — HART 1.4 46.2 CFRT 2 60 11 Dische et al. [7 ] United Kingdom 918 687/231 — — Nasal sinus Nasopharynx Oral cavity Oropharynx Hypopharynx Larynx T1–T4 N0–N3 HART 1.5 54 CFRT 2 66 12 Bartelink et al. [10 ] Netherlands 49 38/11 — — Oral cavity Oropharynx Larynx Hypopharynx T2–T4 — HART 1.6 72 CFRT 2 70
Notes: “–,” not mentioned. CFRT, conventional fractionation radiotherapy; HART, accelerated hyperfractionated radiotherapy.